This Practice Point commentary discusses the study by Denzinger et al. in which patients with high-grade T1 (HGT1) bladder cancer were treated by transurethral resection with either white-light ...

Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...

Histological analysis of the resected specimen diagnosed a Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) with mild lymphocytic submucosal inflammation. Crucially, there was no ...

Background: A 59-year-old female presented with a history of recurrent superficial bladder cancer. Since the initial diagnosis 12 years earlier, she had had 12 recurrences, all treated with ...

Enhanced cystoscopy at the time of cystectomy and in the outpatient surveillance setting increases detection of high-grade NMIBC. The use of enhanced cystoscopy both in the operating room at the time ...

Hepatitis E Infection From Plasma Exchange Recommendations for diagnosing and managing non-muscle invasive bladder cancer promise to allow for more individualized patient care. Newly released clinical ...

Bladder cancer begins in the bladder, a central organ in the urinary system. The National Cancer Institute reports that 14,880 people will die from bladder cancer and 73,510 new cases of the disease ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., announces the commercial launch of the PDD Blue Light Flexible Video Cystoscopy System for enhanced detection of non-muscle ...

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light ...